Literature DB >> 26485685

Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer.

Aiqin Gu1, Jianhong Lu2, Weimin Wang1, Chunlei Shi1, Baohui Han3, Ming Yao4.   

Abstract

The malignancy of non-small cell lung cancer (NSCLC) is largely due to its invasion. Hence, prevention of the cancer cell invasion, which is essentially regulated by vascular endothelial growth factor A (VEGF-A), is substantially critical for a successful treatment for NSCLC. Here, we showed that compared to other cancers, NSCLC had a significant higher ratio of VEGF-A protein vs mRNA, and significantly lower levels of miR-497, suggesting presence of a post-transcriptional control of VEGF-A in NSCLC different from other cancers. Compared with paired normal lung tissue, NSCLC expressed lower levels of miR-497 and higher levels of VEGF-A. Moreover, the levels of miR-497 and VEGF-A were inversely correlated in NSCLC specimen. Bioinformatics analyses showed that miR-497 bound to 3'-UTR of VEGF-A mRNA in NSCLC lines to inhibit its translation. Overexpression of miR-497 in NSCLC lines decreased VEGF-A protein, while depletion of miR-497 in NSCLC lines increased VEGF-A protein. However, modification of miR-497 levels in NSCLC lines did not alter VEGF-A mRNA levels. Overexpression of miR-497 in NSCLC lines inhibited cell growth and invasion, while depletion of miR-497 in NSCLC lines increased cell growth and invasion. Together, our data demonstrate a previously unappreciated role for miR-497 in suppression of VEGF-A-mediated NSCLC cancer cell growth and invasion.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioinformatics analyses; MiR-497; MiRNAs; Non-small cell lung cancer (NSCLC); Vascular endothelial growth factor A (VEGF-A)

Mesh:

Substances:

Year:  2015        PMID: 26485685     DOI: 10.1016/j.biocel.2015.10.013

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  21 in total

1.  Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p.

Authors:  Yi Zhang; Fei Chen; Liang Wang
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase.

Authors:  Hui Yang; Xiao-Li Wu; Kai-Hua Wu; Rong Zhang; Li-Li Ju; Ying Ji; Yan-Wei Zhang; Song-Lin Xue; Ye-Xin Zhang; Yong-Feng Yang; Min-Min Yu
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.

Authors:  Haihong Pu; Qingyuan Zhang; Chunbo Zhao; Lei Shi; Yan Wang; Jingxuan Wang; Minghui Zhang
Journal:  Pathol Oncol Res       Date:  2017-07-25       Impact factor: 3.201

4.  Recombinant human erythropoietin accelerated the proliferation of non-small cell lung cancer cell lines and reduced the expression of VEGF, HIF-1α, and PD-L1 under a simulated hypoxic environment in vitro.

Authors:  Yajing Zhang; Yangchun Feng; Xiaojie Sun
Journal:  Chronic Dis Transl Med       Date:  2022-03-31

5.  MiR-497 enhances metastasis of oral squamous cell carcinoma through SMAD7 suppression.

Authors:  Jun Hu; Jun-Feng Xu; Wei-Li Ge
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

6.  MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.

Authors:  Juhua Zhuang; Ying Ye; Guoyu Wang; Jing Ni; Saifei He; Cuihua Hu; Wei Xia; Zhongwei Lv
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 3.423

7.  Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.

Authors:  Henghui Cheng; Jin Xue; Shouhua Yang; Yaobin Chen; Yu Wang; Yuanli Zhu; Xiaoyan Wang; Dong Kuang; Qiurong Ruan; Yaqi Duan; Guoping Wang
Journal:  Oncotarget       Date:  2017-07-18

8.  miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor.

Authors:  Wei Ma; Weiye Feng; Jie Tan; Airu Xu; Yudong Hu; Lanlan Ning; Yanhong Kang; Liuqian Wang; Ziwen Zhao
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 9.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

Review 10.  miR-497 expression, function and clinical application in cancer.

Authors:  Gang Yang; Guangbing Xiong; Zhe Cao; Suli Zheng; Lei You; Taiping Zhang; Yupei Zhao
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.